Advertisements


Pharma cos leaning on $850,000 therapy to justify super-expensive drugs

An influx of very expensive drugs that offer a one-time cure, such as a hepatitis C therapy from Gilead Sciences, has already stretched state and federal budgets.....»»

Category: topSource: business-standardJan 13th, 2018

Big Pharma is quietly enlisting professors to justify $1,000-per-day drugs

Reuters/Gary CameronOver the last three years, pharmaceutical companies have mounted a public relations blitz to tout new cures for the hepatitis C virus and persuade insurers, including government programs such as Medicar.....»»

Category: topSource: businessinsiderFeb 24th, 2017

Pharma companies increase investments for global biosimilar push

Biosimilars are made from living cells and are far more complex and expensive to manufacture than generic drugs.....»»

Category: topSource: business-standardOct 24th, 2016

Over-the-counter route to accelerate sales growth for domestic pharma firms

Relaunching older prescription drugs in the OTC space allows companies to overcome sluggish prescription growth and also extend life of mature brands.....»»

Category: topSource: business-standardJan 15th, 2018

Drugmakers see a pricing blueprint in an $850,000 gene therapy

SAN FRANCISCO (Reuters) - Global drugmakers are looking to a tiny biotech's $850,000 therapy for a rare type of blindness as a model for getting paid for highly expensive – and effective – new medicines......»»

Category: topSource: reutersJan 12th, 2018

Pharma companies focus on limited competition drugs for the US market

Companies are sharing their strategy at JP Morgan Conference.....»»

Category: topSource: business-standardJan 9th, 2018

A Big Pharma-funded charity that helps patients pay for drugs just sued the government

A Big Pharma-funded charity that helps patients pay for drugs just sued the government.....»»

Category: topSource: washpostJan 8th, 2018

Biggest blockbuster drugs of all time

Lipitor, Humira and Advair boosted the bottom lines of Big Pharma companies and their shareholders for years......»»

Category: topSource: moneycentralJan 5th, 2018

Spark’s Gene-Therapy Pricing Should Spark a Pharma Trend: Gadfly

Spark’s Gene-Therapy Pricing Should Spark a Pharma Trend: Gadfly.....»»

Category: topSource: washpostJan 3rd, 2018

Indian pharma should look beyond generics

Players need to step up investment in newer areas such as specialty drugs and biosimilars.....»»

Category: topSource: business-standardJan 3rd, 2018

Big pharma accused of price gouging life-saving drugs

Last January, shortly before hi.....»»

Category: topSource: foxnewsJan 2nd, 2018

An industry insider just blew the lid off the racket that makes American drugs so expensive

Reuters On a private Bank of America conference call, one healthcare industry insider explained how secret relationships within the industry contributed to the high cost of pharmaceuticals. The relationships he describ.....»»

Category: topSource: businessinsiderDec 23rd, 2017

Pharma Stock Roundup: Aerie"s Rhopressa Approved, Label Expansion for BMY, Pfizer Drugs

Zacks.....»»

Category: topSource: redinewsDec 22nd, 2017

Spark Therapeutics Lacks Catalysts, Says Goldman Sachs

Goldman Sachs is downgrading Spark Therapeutics Inc (NASDAQ: ONCE) after the pharma startup presented disappointing data on its hemophilia A gene therapy at the annual meeting of the American Socie Latest Rat.....»»

Category: blogSource: benzingaDec 14th, 2017

Bumper crop of new drugs fails to lift big pharma R&D returns

LONDON (Reuters) - It is shaping up to be a bumper year for drug approvals, with U.S. officials clearing twice as many novel medicines as in 2016, yet returns on research investment at leading pharmaceutical companies are down......»»

Category: topSource: reutersDec 13th, 2017

Sun Pharma"s specialty drugs face competition in US

The Mumbai-based pharma major reported 59% decline in its net profit for the quarter ending September to Rs 912 cr.....»»

Category: topSource: business-standardDec 12th, 2017

Gilead: The Follower Becomes the Leader?

Gilead's recently acquired Kite Pharma unit reported data about its CAR-T therapy study today......»»

Category: blogSource: barronsDec 12th, 2017

Big Pharma Vs Hemp Based CBDs and Medical Marijuana

Big Pharma Vs Hemp Based CBDs and Medical Marijuana $LLY, $GWPH The legal status of CBD oil, as a nutritional supplement is being threatened by Big Pharma seeking FDA approval for CBD-containing drugs The cannabinoids in cann.....»»

Category: topSource: livetradingnewsDec 11th, 2017

Spark Therapeutics shares slide more than 40% after hemophilia data disappoint

Shares of gene therapy biotech Spark Therapeutics Inc. tumbled more than 40% in early trade Monday, after it reported data from trials of a hemophilia treatment that analysts said look less competitive than a rival product from BioMarin Pharma.....»»

Category: topSource: marketwatchDec 11th, 2017

iPhone: Super-Cycle Or Super Expensive?

iPhone: Super-Cycle Or Super Expensive?.....»»

Category: topSource: seekingalphaDec 8th, 2017

100 hot tech gifts under $100

The Insider Picks team writes about stuff we think you'll like. Business Insider has affiliate partnerships, so we get a share of the revenue from your purchase. Tech doesn't have to be super expensive. You can find a.....»»

Category: topSource: businessinsiderDec 7th, 2017